Mais recentes

  • Transform ▪ The 28th Anniversary Celebration of " Transform"TIENS Group and the 2023 Global Carnival Summit Held

    The "Transform ▪ The TIENS 28th Anniversary Celebration and 2023 Global Carnival Summit with the theme of 'Transform' were successfully held in September, . More than 5000 offline distributors from around the world gathered here to participate in the grand event. During the conference, TIENS Group will conduct synchronous live streaming and relay to over 110 countries and regions around the world, achieving the sharing of globalization across borders, multiple languages, and diverse cultures. More than 20 million people participated online to jointly open the "Third Entrepreneurship and New Tr
  • Codificação a Laser CYCJET para Embalagens de Alimentos, Escolta de Segurança Alimentar!

    Devido à ocorrência frequente de questões de segurança alimentar, como assegurar a qualidade dos alimentos tornou-se um tópico recorrente. A data de produção e o prazo de validade das embalagens de alimentos foram apagados e adulterados, e a prevalência de produtos falsificados tornou difícil proteger os consumidores. A máquina da marcação a Laser da CYCJET ajuda na construção da segurança alimentar.
  • Apresentação da impressora de tinta pigmentada a jacto CIJ da CYCJET

    Como bem sabemos, as impressoras a jacto de tinta para caracteres pequenos penetraram em aplicações em várias indústrias e áreas. Desde a mais simples data em alimentos, prazo de validade, número de série, imagem, código 1D, código QR, ao código pulverizado para identificação. Cobrindo basicamente todas as indústrias alimentares, químicas, farmacêuticas, electrónicas, tubagens, cabos e outras. Portanto, hoje falarei principalmente sobre as dificuldades das impressoras a jacto de tinta para caracteres pequenos - impressoras a jacto de tinta de tinta branca.
  • Aplicação da Impressora a Jacto de Tinta UV CYCJET sobre a Impressão da Lista de Ingredientes Alimentares

    Existem muitos tipos de materiais de embalagem de alimentos e que vão desde o plástico, ao vidro, ao metal, ao cartão e a outros tipos. Só os plásticos incluem polietileno (PE), polietileno de baixa densidade (PEBD), polietileno de alta densidade (PEAD), polipropileno (PP), polipropileno biaxialmente orientado (OPP), poliestireno (PS), cloreto de polivinil (PVC), cloreto de polivinilideno (PVDC), poliéster (PET), nylon (NY) ou uma película composta de vários dos exemplos acima referidos.
  • Aplicação da Impressora de Jato de Tinta CYCJET C702 na Impressão de Embalagens Cartonadas

    Na nossa vida, existem muitos produtos em embalagem cartonada. Coisas como as caixas de tabaco e álcool, caixas de presente, caixas de embalagem de alimentos, caixas de medicamentos, vários móveis grandes, embalagens de cartão, etc. Pode verificar-se que a embalagem cartonada é também um material indispensável, e a impressora de jato de tinta para cartão tornou-se um destaque da indústria de embalagens.
  • Série CYCJET M Máquina Portátil de Marcação a Laser - Novas Tecnologias na Indústria de MarcaçãoSérie CYCJET M Máquina Portátil de Marcação a Laser - Novas Tecnologias na Indústria de Marcação

    A impressora a laser inteligente portátil Série CYCJET M é mais pequena, inteligente e portátil com um design bem compacto, com apenas peças portáteis e caixa de controlo com tamanho pequeno. Possui um potente sistema de alimentação com bateria de lítio de 24V que pode alimentar a impressora de forma completa e estável a funcionar!
  • Inauguração da Exposição Digital do Comércio Internacional China-América Latina de 2022

    No dia 20 de Setembro de 2022 foi inaugurada a Exposição Digital de Comércio Internacional China-América Latina na plataforma B2B A exposição é organizada pelo China Council for the Promotion of International Trade e co-realizada pela China Chamber of International Commerce e pela Jiangsu United Asia International Exhibition Co., Ltd. Esta exposição digital contará com um modelo inovador de 10 dias de exposição online + 30 dias de comércio online + 365 dias de exposição online. Tem por objectivo aprofundar a cooperação em campos tradicionais, expandir a cooperação em indús
  • GEM, a Leading Green Enterprise in China, will land on the Swiss Exchange

    GEM (stock code: 002340), a company listed on the Shenzhen Stock Exchange, announced that on June 22, 2022, that the China Securities Regulatory Commission (CSRC) gave its approval for the company to issue global depository receipts (GDR) and to be listed on the Swiss Exchange (SIX). On July 20, 2022, SIX approved GEM to issue GDR and to be listed on the SIX. So far, the path of GEM issuing GDR and going public on the SIX have been unimpeded.


Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes


Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celartics research team, demonstrate that using the proprietary engineered DC technology by targeting nucleoprotein (NP) of COVID-19, NP-specific cytotoxic CD8+ T cells from naive T lymphocytes can be efficiently induced and massively expanded in culture. The antigen-loaded DCs and viral antigen-specific T cells have great potentials in preventing viral infection and in controlling progression of virus-associated diseases, respectively.

Dendritic cells are the most potent professional antigen-presenting cells that can engulf and process viral or tumor antigens. Once DCs are loaded with viral antigen and become activated, they acquire the ability to educate naïve T lymphocytes, promoting these T cells to differentiate into antigen-specific cytotoxic T cells that can fight virus. Primary blood DCs constitute 1% of immune cells in peripheral blood and are not able to grow in culture. Manufacturing clinical grade DC with the conventional DC method, therefore, needs quite large amount of blood and is very costly, limiting DC’s application as a preventive vaccine against viral infection. To overcome various technical hurdles associated with the conventional DC method, Celartics Biopharma has developed an innovative engineered DC technology, which enables primary blood DCs from a few milliliters of peripheral blood to grow in culture, generating large amounts of highly activated DCs suitable for multiple clinical applications. These engineered DCs exhibit vastly improved antigen-loading capability and efficient lymphoid tissue homing ability due to high expression of the chemokine receptor, CCR7. In addition, the manufacturing cost for generating engineered DCs is significantly reduced. “The engineered DCs are safe to use, as demonstrated in animal studies and pilot clinical trial in cancer immunotherapy”, said Yang Yu, CEO of Celartics Biopharma

Current vaccine strategies for COVID-19 include mRNA vaccine, DNA vaccine, adenovirus vector-based vaccine and inactivated virus vaccine, with the goal of generating neutralizing antibody that reacts to Spike, the viral surface protein of COVID-19. The neutralizing antibody blocks entry of virus to host cells through ACE2 receptor. Accumulating evidences have suggested that developing permanent immunity remains challenging, exclusively by targeting heavily glycosylated Spike protein or rapidly mutating viral surface proteins such as influenza HA. Differing from these vaccine strategies, the engineered DCs are designed to empower T cells to fight virus. DC-educated T cells recognize viral antigenic peptides complexed with HLA molecules on the surface of virus-harboring host cells and launch subsequent attack to eliminate virus. Furthermore, a given viral protein in host cells is processed into multiple antigenic peptides that are bound to distinct HLA molecules, this provides many targets for antigen-specific T cells to attack. Unlike Spike protein, the NP protein of COVID-19 is less likely to mutate and also share 91% amino acid sequence homology with the counterpart of SARS virus. “The Cov-DCVax is designed to develop long-lasting protective immunity in human to fight both COVID-19 and SARS viruses”, said Yang Yu.

In last February, Celartics Biopharma announced the development of Human Dendritic Cell and Data Repository (HDCR), in order to meet urgent demands in fighting deadly virus outbreak and cancer. HDCR prepares human blood dendritic cells from healthy individuals in GMP facility, coupled with data analysis covering immunophenotyping and HLA typing. These engineered DCs are stored in liquid nitrogen and are readily available when needed, in supporting cell-based vaccination or immunotherapy. HDCR also serves as the platform technology provider to research institutions and pharmaceutical industries. The ultimate goal of HDCR is to bring in a feasibility of dendritic cells as a new form of preventive vaccines for rapidly evolving viruses. The Cov-DCVax vaccine is intended for generating long-lasting protective immunity in high risk individuals, while the viral antigen-specific T cells provide immediate therapeutic protection in controlling the progression of COVID-19-associated disease. "The current research progress and patent application enhance the spectrum of possible collaborators and partners. We are delighted that our scientific team has made solid progress in developing such unique Cov-DCVax vaccine, which may potentially yield benefits useful to high risk population, considering current global impact and severity of COVID-19 pandemic", said Yang Yu, CEO of Celartics Biopharma.

About Celartics Biopharma, Inc. Celartics Biopharma is a biotechnology company, located at Dongsheng International Science Park, Beijing. The company focuses on developing innovative cell-based immunotherapies for human cancer and viral diseases. The Company seeks rapidly advancing these technologies through pre-clinical and Phase I and II clinical trials, centering on DC therapeutic vaccine and adoptive T cell transfer therapies for treating solid cancer and leukemia. The company also seeks potential collaborators and partners for joint development through the proprietary technology platforms.

Ph.D., Chief Technology Officer, Celartics Biopharma, Inc.

Company :Celartics Biopharma Inc., Ltd.  

Contact: Huan Zhang,

Phone:010-6295 5880



Declaração: Este artigo é reproduzido em outras mídias. O objetivo da reimpressão é transmitir mais informações. Isso não significa que este site concorda com suas opiniões e é responsável por sua autenticidade, e não tem nenhuma responsabilidade legal. Todos os recursos deste site são coletados na Internet. O objetivo do compartilhamento é apenas para o aprendizado e a referência de todos. Se houver violação de direitos autorais ou propriedade intelectual, deixe uma mensagem.
Voltar ao topo
© Direito autoral 2009-2020 Diariamente em português      Contate-nos   SiteMap